natgillin/translations-raw huggingface dataset:
and R2 are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl and optionally substituted heteroaryl; is COR7; and 
R' i R> se neovisno biraju iz skupine koju čine vodik, opcionalno supstituirani alkil, opcionalno supstituirani karbociklički spoj, opcionalno supstituirani heterociklički spoj, opcionalno supstituirani aril i opcionalno supstituirani heteroaril; R' je COR/; i
According to one embodiment, the Micafungin starting material and the aqueous solution in step b) of the present method comprises 2-30% v/v of a water miscible organic solvent. 
Postupak prema zahtjevu 1, naznačen time da vodena otopina sadrži otopljenu sol Micafungina u koraku a) i vodena otopina u koraku b) prema predmetnom postupku sadrži 2-30% v/v organskog otapala koje se miješa s vodom.
In another embodiment of the invention, the composition wherein a therapeutically effective amount of the composition is to be administered prior to, concurrent to, or subsequent to other active agent(s) for treating Parkinsonian Syndromes and/or side effects of said active agent(s). 
Pripravak za uporabu sukladno zahtjevu 1 ili 2, naznačen time, da je terapeutski učinkovita količina pripravka primjenjivati prije, istodobno ili nakon drugog aktivnog sredstva (a) za liječenje bolesti s Parkinsonovim sindromima i / ili nuspojave navedenog aktivnog sredstva (sredstava).
The process according to claim 5, wherein the compound of formula (V) is obtained by reacting compound of formula (IV) with C1-4-alkanol and an acid catalyst. The process according to claim 5, wherein the compound of formula (IV) is obtained by reacting compound of formula (III) with benzyl alcohol; in the presence of a coupling agent; or in the presence of an C1-4-alkylchloroformate of the formula ClCOOR″, wherein R″ is C1-4-alkyl, such as methyl, ethyl, 1-propyl, 1-butyl, 2-butyl, and an organic base. 
Postupak prema bilo kojem zahtjevu 4 ili 6, naznačen time da je spoj formule (V) dobiven reakcijom spoja formule (IV) sa Crvalkanolom i kiselim katalizatorom; te pri čemu je spoj formule (TV) dobiven reakcijom spoja formule (II) sa benzil alkoholom; u prisutnosti reakcijskog sredstva ili u prisutnosti C,galkilkloroformata formule CICOOR", pri čemu R" je Craalkil, kao metil, etil, 1-propil, 1-butil, 2-butil, i organske baze.
The fusion protein according to claim 1 wherein B is the immunogenic fragment of PilA consisting of amino acids 40-149 from SEQ ID NO. 58. The fusion protein according to claim 1 wherein A is SEQ ID NO. 125. 
Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je B imunogeni fragment PilA koju čine aminokiseline 40-149 from any of SEQ ID NO. 58-SEQ ID NO. 121.
an adjustment mechanism secured to the frame and coupled to one of the tire inflating chuck rings from each pair of inflator stations to adjust a vertical position of said one of the tire inflating chuck rings from each pair of inflator stations relative to the frame, 
Uređaj za pumpanje gume nakon vulkanizacije prema patentnom zahtjevu 1, naznačen time da dalje sadrži mehanizam za podešavanje (70) koji je pričvršćen za okvir (34) i koji se koristi za podešavanje vertikalne pozicije spomenutog steznog prstena za pumpanje guma (30B, 32A) koji je pričvršćen za okvir (34).
Typical fragrances include aromatic materials extracted from botanical sources (i.e., rose petals, gardenia blossoms, jasmine flowers, etc.) 
Tipični mirisi uključuju aromatske materijale dobivene od botaničkih izvora (tj., ružinih latica, cvjetova gardenije, cvjetova jasmina, itd.
"aryloxy" refers to an aryl or a substituted aryl group bonded directly through an alkoxy group; 
"ariloksi" označava aril ili supstituiranu aril skupinu vezanu direktno preko alkoksi skupine;
In an embodiment having a control and the plurality of accommodations, optionally, at least one of the plurality of accommodations comprises an identification detector, such as an RFID reader, to determine for the control an identity of a perfume in a module having an RFID and accommodated at any particular time in the accommodation having the identification detector. 
Sklop u skladu sa patentnim zahtjevima 5 i 6, gdje najmanje jedan od navedenih više prijemnih dijelova sadrži detektor za identifikaciju, kao što je RFID čitač, kako bi se odredila kontrola identiteta parfema u modulu koji ima RFID i smještenog u bilo koje određeno vrijeme u navedeni prijemni dio koji ima navedeni detektor za identifikaciju.
an oligosaccharide which is a homotrimer, heterotrimer, homotetramer and/or heterotetramer comprising 3 or 4 saccharide monomers selected from the group consisting of a pentose saccharide, a hexose saccharide, glucuronic and galacturonic acid, and wherein the saccharide monomers are connected by means of a and/or B bonds; and 
- homo-trimer, hetero-trimer, homo-tetramer i/ili hetero-tetramer ugljikohidratne komponente, ili njezin oksidirani oblik, ili njihove smjese, gdje se ta ugljikohidratna komponenta izabire iz grupe koju čini saharid pentoza izabran između riboze, arabinoze, ksiloze ili liksoze, saharid heksoza izabran između aloze, altroze, guloze, idoze, taloze ili manoze, glukuronska kiselina i galakturonska Kiselina, i gdje su ugljikohidratne komponente povezane preko a i/ili B veza; i
After filtration the solvent is removed in vacuo to give the titled product which is used crude in the next step. 
Nakon filtracije otapalo se odstrani u vakuumu, čime se dobije naslovni proizvod koji se sirov upotrebljava u slijedećem stupnju.
The titled compound is prepared analogously to 4-fluoro-3-methoxy-benzenesulfonyl chloride (Intermediate 102a) by replacing 4-fluoro-3-methoxyaniline with 3-amino-4-chloro-benzonitrile. 
Naslovni spoj je proizveden analogno 4-fluor-3-metoksi-benzensulfonil kloridu (intermedijat 102a) zamjenom 4-fluor-3-metoksianilina s 3-amino-4-klorbenzonitrilom.
The compounds appear to be particularly active as inhibitors of dihydrofolate reductase. 
Pokazalo se da su spojevi posebno učinkoviti kao inhibitori dihidrofolat reduktaze.
The compound according to claim 1, having an X-ray diffraction pattern, expressed in terms of 2 θ angles, that includes five or more peaks selected from the group consisting of about 10.2, 12.7, 14.0, 14.7 and 15.2±0.02 degrees. 
Spoj u skladu s patentnim zahtjevom 11, naznačen time što ima uzorak difrakcije rendgenskih zraka, dan u terminima kutova 26, sa signalima na 6,0, 7,5, 8,5, 12,3, 16,0, 17,0, 18,0, 18,2, 18,7, 23,2 125,2 + 0,2 stupnja.
Process according to any of claims 1 to 9, characterized in that said water-soluble acid(s) of step b) are dosed in a total amount corresponding to 5 to 40 wt.-% equivalent pure acid based on the dry weight of GNCC provided in step a), more preferably in a total amount corresponding to 10 to 30 wt.-% equivalent pure acid based on the dry weight of GNCC provided in step a), and most preferably in a total amount corresponding to 15 to 25 wt.-% equivalent pure acid based on the dry weight of GNCC provided in step a). 
Postupak prema bilo kojem od zahtjeva 1 do 9, naznačen time da sc navedena kiselina ili navedene kiseline topivo u vodi iz koraka b) doziraju u ukupnoj količini koja odgovara 5 do 40 % tež. ekvivalenta čiste kiseline bazirano na težini suhog GNCC osiguranog u koraku a), poželjnije u ukupnoj količini koja odgovara 10 do 30 % tež. ekvivalenta čiste kiseline bazirano na težini suhog GNCC osiguranog u koraku a), te najpoželjnije u ukupnoj količini koja odgovara 15 do 25 % tež. ekvivalenta čiste kiseline bazirano na težini suhog GNCC osiguranog u koraku a).
a third software module executable by the processor and the memory, the third software module configured to generate a repair model for repairing the invalid field of the portable executable file; and a fourth software module executable by the processor and the memory, the fourth software module configured to repair the invalid field of the portable executable file based upon, at least in part, the repair model, wherein repairing the invalid field of the portable executable file includes correcting the invalid field of the portable executable file via one or more algorithms; 
Sustav koji sadrži: procesor; memoriju spojenu sa procesorom; prvi softverski modul izvršiv putem procesora i memorije, prvi softverski modul konfiguriran da identificira (100) nevažećeg polje prijenosne izvršne datoteke uspoređivanjem atributa polja spomenute prijenosne izvršne datoteke sa važećim karakteristikama važećih odgovarajućih polja kako je navedeno u specifikacijama formata prijenosne izvršne datoteke; drugi softverski modul izvršiv putem procesora i memorije, drugi softverski modul konfiguriran da odredi (102) vjerojatnost popravka nevažećeg polja prijenosne izvršne datoteke utvrđujući (114) broj i karakteristike
separating plurality of cells from fermentation broth or harvest by centrifugation; 
razdvajanje pluraliteta stanica iz fermentiranog preparata ili prinosa centrifugiranjem (101);
The process of Claim 1, where a is 0, R3 and R5 are hydrogen, and R4 and R6 are fluoro. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da a je 0, R3 i R5 su vodik a R4 i R6 su fluoro.
Figure 2: View of the cannulated screw. 
Broj objave europskog patenta:
The back part 71 of the inner part composes the hinge connection between the two sides, and the back part is covered by a metal part/layer 72. 
Stražnji dio 71 unutarnjeg dijela tvori spoj koji predstavlja zglobni spoj i nalazi se između dvije strane, i pri čemu je stražnji dio prekriven metalnim dijelom/slojem 72.
The compound of claim 1, where R1 is isobutyl, cyclopentyl, or thiophenyl. 
Spoj iz Patentnog zahtjeva 1, naznačen time, da je R' izobutil, ciklopentil ili tiofenil.
Expression of the recombinant proteins: 
Datum objave europskog patenta:
R1' is linear or branched C1-C4 alkyl or C3-C4 cycloalkyl, each of said alkyl or cycloakyl groups being optionally substituted by one or more group(s) selected from halo or esters; 
’ je linearni ili razgranati C1-C4 alkil ili C3-C4 cikloalkil, svaka od navedenih alkil ili cikloakil grupe sup o izboru supstituirane jednom ili više grupa izabranih iz halo ili esteri;
R1f is a hydrogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkenyl group or a lower alkanoyl group; is a lower alkyl group, a lower alkenyl group, a lower alkynyl group or a cyclo-lower alkyl group optionally substituted by a halogen atom, or is an aryl group, an aralkyl group or a heteroaromatic group optionally having a substituent selected from a group consisting of a halogen atom, a cyano group, an amino group and a lower alkyl group; 
f je atom vodika, niža alkilna skupina, halo-niža alkilna skupina, niža alkenil skupina ili niža alkanoil skupina; je niža alkilna skupina, niža alkenil skupina, niža alkinil skupina ili ciklo-niža alkilna skupina po izboru supstituirana halogen atomom, ili je aril skupina, aralkil skupina ili heteroaromatska skupina koja po izboru ima supstituent odabran iz grupe koju čine halogen atom, cijano skupina, amino skupina i niža alkilna skupina;
Aspect 32. A method for making a host cell for production of a heterodimeric Ig-like molecule, the method comprising the step of introducing into said host cell nucleic acid sequences encoding at least a first and a second CH3-domain comprising polypeptide chain, wherein said first CH3 domain-comprising polypeptide chain comprises at least one substitution of a neutral amino acid residue by a positively charged amino acid residue and wherein said second CH3 domain-comprising polypeptide chain comprises at least one substitution of a neutral amino acid residue by a negatively charged amino acid residue, wherein said nucleic acid sequences are introduced consecutively or concomitantly. 
Postupak za pripremu stanice domaćina za proizvodnju najmanje dva različita antitijela, pri čemu postupak sadrži korak uvođenja u navedenu stanicu domaćina sekvenci nukleinske kiseline koje kodiraju najmanje prvi, drugi, treći i četvrti polipeptidni lanac koji sadrži CH3 domenu, pri čemu navedeni prvi polipeptidni lanac koji sadrži CH3 domenu sadrži CH3 domenu humanog IgG koji sadrži lizinski (K) ostatak na aminokiselinskom položaju 366 u skladu s EU sustavom numeracije i pri čemu navedeni drugi polipeptidni lanac koji sadrži CH3 domenu sadrži CH3 domenu humanog IgG koji sadrži ostatak asparaginske kiseline (D) na aminokiselinskom položaju 351 u skladu s EU sustavom numeracije, pri čemu navedene sekvence nukleinske kiseline su uvedene uzastopno ili istovremeno.
The method of claim 2, wherein the phospholipid is one or more of sphingomyelin, dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylglycerol (DPPG). 
Peptid ili farmaceutski prihvatljiva sol peptida prema zahtjevu 4, naznačen time da je lipid smjesa sfingomijelina, dipalmitoilfosfatidilkolina (DPPC) i dipalmitoilfosfatidilglicerola (DPPG).
The method of claim 5, wherein the B-lactamase inhibitor is in the form of a sodium salt. 
Kombinacija za uporabu sukladno patentnom zahtjevu 4 ili patentnom zahtjevu 5, naznačena time što je inhibitor B-laktamaze u obliku natrijeve soli.
A compound according to any one of claims 1 to 28 for use in the treatment of a pathological condition or disease associated with B2 adrenergic receptor agonist and muscarinic receptor antagonist activities, which condition or disease is preferably selected from pulmonary diseases, pre-labor, glaucoma, neurological disorders, cardiac disorders, inflammation and gastrointestinal disorders, and is more preferably asthma and or chronic obstructive pulmonary disease. 
Spoj prema bilo kojem zahtjevu od 1 do 11 za primjenu u liječenju patološkog stanja ili bolesti povezane s djelovanjem agonista B2 adrenergičkog receptora i antagonista muskarinskog acetilkolinskog receptora M3, pri čemu je stanje ili bolest poželjno odabrano iz plućnih bolesti, prijevremenog poroda, glaukoma, neuroloških poremećaja, srčanih poremećaja, upalnih ili gastrointestinalnih poremećaja, a poželjnije je astma ili kronična opstruktivna plućna bolest.
SR6 wherein R6 is Vn-heteroaryl, n is 0, and the heteroaryl group is a 9-10 membered bicyclic heteroaromatic ring having 2-3 atoms independently selected from N, S and O, and optionally substituted with one or two groups independently selected from I, Br, C1-C6 alkyl and CO2H; 
SR" gdje Rs je V,-heteroaril, n je 0, i heteroarilna skupina je 9-10-eročlani biciklički heteroaromatski prsten s 2-3 atoma nezavisno izabrana između N, S i O, i po izboru supstituiran s jednom ili dvije skupine nezavisno izabrane između I, Br, C,-Cg alkil i CO2H;
*and wherein R12 and R13 can be taken together in order to form a (5-, 6-, or 7-membered) heterocycle which can be unsubstituted or substituted; 
* i pri čemu R i R1 se mogu uzeti zajedno tako da tvore (5-, 6-, ili 7-člani) heterocikal koji može biti nesupstituiran ili supstituiran;
is selected from the group consisting of hydrogen, fluoro, hydroxy, and methoxy; 
Spoj prema zahtjevu 11, naznačen time, da je odabran iz sljedeće skupine:
A method of killing cancer cells in a subject, comprising the step of providing to the subject a therapeutically effective amount of the peptide of any one of items 1 to 3, the nucleic acid of any one of items 4, 5 and 33, the cell of any one of items 6, 7 and 35, the immunoreactive cell of item 8, the binding agent of item 9, the T cell receptor of any one of items 10 to 13, or the artificial T cell receptor of any one of items 14 to 32. 
Peptid sukladno patentnom zahtjevu 1 ili 2, nukleinska kiselina sukladno patentnom zahtjevu 3 ili 12, stanica sukladno patentnom zahtjevu 4 i 13, T stanični receptor sukladno patentnom zahtjevu 5, ili stanični T receptor sukladno bilo kojem od patentnih zahtjeva 6 do 11, za uporabu u postupku uništavanja stanica raka kod subjekta, koji sadrži korak osiguranja terapeutski učinkovite količine peptida, nukleinske kiseline, stanice, T staničnog receptora ili umjetnog Tstaničnog receptora kod subjekta.
and R2 form a cyclopentane ring or a tetrahydropyran ring together with an adjacent carbon atom; 
R; i R, tvore ciklopentanski prsten ili tetrahidropiranski prsten zajedno sa susjednim ugljikovim atomom;
Even more preferably, the colour of the thermochromic ink is, below the predetermined temperature, as similar as possible to that of the conventional ink. 
Pakirni materijal (11) prema bilo kojem od zahtjeva 1, 2 ili 3, naznačen time, da je obojenje termokromne tiskarske boje ispod spomenute predodređene temperature, što je više moguće slično onom obojenju od konvencionalne tiskarske boje.
A compound of Formula I: wherein: is pyridyl, pyrimidinyl, or pyrazinyl, attached through a carbon atom of the heteroaryl ring, optionally substituted with 1, 2, or 3 R5, or 
naznačen time da: Rl je piridil, pirimidinil ili pirazinil, vezan preko ugljikovog atoma heteroarilnog prstena, po izboru supstituiran sa 1, 2 ili 3 R5, ili pri čemu R1 je tiofenil, kinolinil, izokinolinil, benzofuranil, benzotiofenil ili pirazolil, svaki po izboru supstituiran sa 1, 2 ili 3 R5;
A pharmaceutical formulation comprising a compound or pharmaceutically acceptable salt thereof according to claim 22 or claim 26 and at least one pharmaceutically acceptable excipient, diluent or carrier, optionally further comprising another anticancer agent. 
Farmaceutska formulacija, naznačena time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1-25, kao i najmanje jednu dodatnu farmaceutski prihvatljivu pomoćnu tvar, razrjeđivač ili podlogu.
As used herein, the term “animal cell” includes human and non-human mammalian cells, non-mammalian cells, recombinant cells and hybridomas. 
Na način na koji se ovdje rabi, pojam,životinjske stanice" obuhvaća ljudske stanice, stanice ostalih sisavaca, stanice koje nisu od sisavaca, rekombinantne stanice te hibridome.
A monoclonal antibody or a functional part thereof, which recognizes and binds to B-amyloid protein, comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 9; a light chain CDR2 having the amino acid sequence of SEQ ID NO: 10; a light chain CDR3 having the amino acid sequence of SEQ ID NO: 11; a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 12; a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 13; and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 14 for use in preventing, treating or alleviating the effects of glaucoma, optic neuritis, or lattice dystrophy. 
Monoklonsko protutijelo, ili njegov funkcionalni dio, koje prepoznaje i veže se na B-amiloidni protein, te sadrži CDRI lakog lanca s aminokiselinskim slijedom SEQ ID NO: 9; CDR2 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 10; CDR3 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 11; CDRI teškog lanca s aminokiselinskim slijedom SEQ ID NO: 12; CDRI teškog lanca s aminokiselinskim slijedom SEQ ID NO: 13;1 CDR3 teškog lanca s aminokiselinskim slijedom SEQ ID NO: 14, naznačeno time što je namijenjeno upotrebi u sprječavanju, liječenju ili ublažavanju posljedica glaukoma, optičkog neuritisa ili retikularne distrofije.
For example, "heteroaryl" includes an optionally substituted six-membered heteroaromatic ring containing 1, 2 or 3 nitrogen atoms condensed with an optionally substituted five- or six-membered carbocyclic or heterocyclic aromatic ring. 
Na primjer, "heteroaril" uključuje eventualno supstituiran šesteročlani heteroaromatski prsten koji sadržava 1, 2 ili 3 dušikova atoma spojen s eventualno supstituiranim petero- ili šesteročlanim karbocikličkim ili heterocikličkim aromatskim prstenom.
The compound of claim 27, wherein R43 and R44 together with the carbon atoms to which they are attached form a C5-C8 cycloalkenyl or a C5-C8 aryl. 
Spoj prema zahtjevu 27, pri čemu Ry 1 Ra zajedno sa ugljikovim atomima za koje su vezani čine Cs-Cg cikloalkenil ili Cs-Cg aril.
The use of the compounds of the formula I as claimed in one or more of claims 1 to 4 for the manufacture of a medicament for the treatment and/or prevention of disorders in which insulin resistance is involved. 
. Spojevi formule I u skladu s jednim ili više patentnih zahtjeva 1 do 23, namijenjeni upotrebi u liječenju i/ili sprječavanju poremećaja kod kojih je uključena otpornost na inzulin.
Preferably the disease or disorder is a tumor-related disease and in particular embodiments is selected from the group consisting of breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, prostate cancer and liver cancer. 
Antitijelo za primjenu iz patentnog zahtjeva 14 konjugat za primjenu iz patentnog zahtjeva 14 ili farmaceutska kompozicija za primjenu iz patentnog zahtjeva 14 gdje bolest ili poremećaj je odabran iz grupe koja se sastoji od raka dojke, raka pluća, raka želuca, raka jajnika i hepatocelularnog raka.
A method for producing a calcium carbonate particle fine fraction from a feed material, the calcium carbonate particle fine fraction, when in a densely compacted bed form, having a monomodal pore diameter distribution and a volume defined median pore diameter from 0.01 to 0.04 micrometre, an intruded total specific void volume of 0.1-0.3 cm3/g, and a volume defined pore size polydispersity expressed as full width at half maximum in the range of 0.01 to 0.03 micrometre, wherein the densely compacted bed is formed in a wet tablet press apparatus from a water slurry of the calcium carbonate particles by applying a constant pressure of 15 bars to the slurry until the water is released by filtration through a 0.025 micrometer filter membrane, and the tablets formed are dried at 60 °C for 24 hours, and wherein the volume defined median pore diameter and the intruded total specific void volume of calcium carbonate particles, when in a densely compacted form, are characterized by mercury porosimetry: 
Postupak za proizvodnju fine frakcije čestica kalcijevog karbonata iz materijala za punjenje, fina frakcija čestica kalcijevog karbonata, kada su u gusto zbijenom sloju, ima monomodalnu razdiobu promjera pora i volumenski definirani srednji promjer pora od 0,01 do 0,04 mikrometara, intrudirani ukupni specifični prazni volumen od 0,1-0,3 cm3/g, i volumenski definiranu polidisperzivnost veličine pora izraženu kao punu širinu pri polovini maksimuma u rasponu od 0,01 do 0,03 mikrometara, pri čemu je gusto zbijeni sloj oblikovan u uređaju za prešanje vlažnih tableta iz vodene suspenzije čestica kalcijevog karbonata primjenom konstantnog tlaka od 15 bara na suspenziju sve dok se voda ne oslobodi filtriranjem kroz 0,025 mikrometarsku filtarsku membranu, a nastale tablete se suše na 60 °C tijekom 24 sata, te pri čemu je volumenski definirani srednji promjer pora i intrudirani ukupni specifični prazni volumen čestica kalcijevog karbonata, kada su u gusto zbijenom obliku, naznačen time što ima živinu porozimetriju:
Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, lubricants, inert diluents, lubricating, surface active or dispersing agents. 
Komprimirane tablete mogu se izrađivati u prikladnom stroju komprimiranjem djelatnog sastojka koji se nalazi u slobodnom rasutom obliku poput praška ili granula, po izboru pomiješan s vezivnim sredstvima, lubrifikantima, inertnim razrjeđivačima, sredstvima za podmazivanje, surfaktantima ili raspršivačima.
4.0% by weight of sodium starch glycolate; and 0.5% by weight of magnesium stearate. 
(iii) 4,0% po masi, natrijevog škrobnog glikolata; i (iv) 0,5% po masi, magnezijevog stearata.
A method for removing calcium from crude oil or its blends containing calcium naphthenate, the method comprising contacting the crude oil or its blends with wash water used in a crude oil processing system and an additive, wherein the wash water has a pH of about 3 to about 11, and wherein the additive consists of glyoxal. 
Metoda za uklanjanje kalcija iz sirove nafte koja sadrži kalcij naftenat pri niskom pH od 3 do 4, i također pri visokom pH od 5 ili više vode za ispiranje koja se koristi u sustavima prerade sirove nafte, naznačena time što se sirova nafta ili njezine mješavine koje sadrže kalcij naftenat tretiraju s aditivom, a aditiv je glioksal.